Neupogen

GPTKB entity

Statements (63)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by injection
gptkbp:approves gptkb:1991
gptkb:FDA
gptkbp:available_on vial
pre-filled syringe
gptkbp:class granulocyte colony-stimulating factor
gptkbp:clinical_trial Phase III
gptkbp:clinical_use preventing infection
enhancing recovery from bone marrow suppression
supporting chemotherapy
gptkbp:compatibility do not mix with other drugs
gptkbp:contraindication gptkb:sickle_cell_disease
hypersensitivity to filgrastim
gptkbp:dosage_form gptkb:Software_Solutions
gptkbp:formulation sterile solution
https://www.w3.org/2000/01/rdf-schema#label Neupogen
gptkbp:indication bone marrow transplant
chemotherapy-induced neutropenia
HIV/ AIDS-related neutropenia
gptkbp:ingredients filgrastim
gptkbp:invention patented
gptkbp:is_a_guide_for ASCO guidelines
NCCN guidelines
ECOG guidelines
gptkbp:is_monitored_by complete blood count
gptkbp:manufacturer gptkb:Amgen
gptkbp:marketed_as gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action stimulates bone marrow
gptkbp:patient_population cancer patients
patients undergoing chemotherapy
patients with bone marrow disorders
gptkbp:pharmacokinetics subcutaneous absorption
reduces infection risk
clearance via kidneys
half-life of 3.5 hours
increases neutrophil count
gptkbp:price varies by region
gptkbp:related_to gptkb:pegfilgrastim
G-CSF
gptkbp:research_areas hematology
cancer supportive care
neutropenia treatment
gptkbp:route_of_administration intravenous
subcutaneous
gptkbp:shelf_life 24 months
gptkbp:side_effect fatigue
headache
nausea
fever
acute respiratory distress syndrome
bone pain
thrombocytopenia
leukocytosis
splenic rupture
gptkbp:storage refrigerated
gptkbp:trade gptkb:Neupogen
gptkbp:used_for treating neutropenia
gptkbp:bfsParent gptkb:Immunex_Corporation
gptkb:Neulasta
gptkbp:bfsLayer 5